- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05569369
Endovasculaire behandeling van gecombineerde gemeenschappelijke femorale en oppervlakkige femorale arteriële laesies
Endovasculaire behandeling van gecombineerde laesies van gemeenschappelijke femorale en oppervlakkige femorale arteriën bij patiënten met chronische ischemie die de onderste ledematen bedreigt
The purpose of this study is to evaluate the technical feasibility, safety, and 1-year clinical efficacy of the endovascular treatment of patients with atherosclerotic common femoral artery (CFA) obstructions with associated superficial femoral artery lesions. Participants will undergo angioplasty with or without stenting of common femoral and superficial femoral arteries.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Study design:
It is a prospective study which will include patients who need revascularization after approval of this study from local ethical committee and obtaining written informed consent.
Study setting:
This study will be done in Sohag University Hospitals and in Cairo University Hospitals.
Study sample:
This study will include 25 patients who present with chronic lower limb threatening ischemia and need endovascular revascularization and met the eligible criteria.
All patients in the study are subjected to the following: - (A) History
Complete history taking from all patients with special concern of the following:
- Age, sex and life style.
- History of diabetes, hypertension, dyslipidemia, stroke and coronary artery disease.
- History of smoking, congestive heart failure and chronic renal disease.
- History of blood diseases and hypercoagulable states.
- History of local or systemic infection.
- History of previous revascularization in the same limb and the other limbs. (B)Examination
General examination:
- General condition.
- Vital signs: - (pulse, blood pressure, temperature, respiration).
- Systemic examination and preoperative medical assessment especially cardiopulmonary and renal systems evaluation.
Local examination:
- Examination of the arterial pulsation all over the arterial tree.
- Measuring ankle brachial index (ABI) and toe brachial index (TBI).
- Examination of any wound and measuring its dimensions. (c) Investigation Including: _
- Complete blood count, lipid profile, fasting blood sugar and HgA1C.
- Bleeding time and coagulation time.
- Prothrombin time and concentration, serum urea and creatinine.
- Echocardiography and ECG.
- Arterial duplex of the affected limb.
- CT angiography of abdominal aorta and both lower limbs unless creatinine clearance (CrCl) is impaired (D) Procedure All procedures will be performed in the operating room by vascular surgeons. Local anesthesia with conscious sedation is indicated, unless general anesthesia is needed in patients who are restless and in pain.
Access to the lesion is achieved either by way of an over-the-aortic bifurcation approach with the use of a dedicated 6-F or 7-F-long sheath (45 cm) or via a brachial approach with the use of a dedicated 6-F or 7-F-long sheath (90 cm) or retrograde via popliteal approach if failed antegrade approach.
After sheath placement, an intravenous bolus of 50 UI kg-1 of heparin is given. Digital subtraction angiography (DSA) is performed to assess lesions. After successful passage of the target lesions with a hydrophilic 0.035-inch guide wire, primary stenting without lesion pre-dilatation is preferably performed. One stenting technique from the CFA to the superficial femoral artery (SFA) may be involved.
The last generation of self-expandable stents eg The Supera stent will be used in common femoral artery lesions.
Balloon-expandable stents are used for associated SFA lesions. Self-expandable stents are routinely post-dilated. The balloon dimensions are chosen such that the nominal diameter is inferior to the stent diameter by 1 mm to reduce medial damage and the length doesn't exceed the stent length. The technical result of the procedure is assessed by DSA.
A prophylactic dose of low-molecular-weight heparin is given during the duration of hospitalization to prevent venous thrombo-embolic events. Postoperatively, patients are prescribed aspirin (75-160 mg day-1) and clopidogrel (75 mg day-1) for 6 months. After 6 months, patients are prescribed only clopidogrel (75 mg day-1).
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Sohag Governorate
-
Sohag, Sohag Governorate, Egypte, 20
- Sohag university
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Serum creatinine < 2.
- Complaining of chronic lower limb threatening ischemia due to denovo atherosclerotic disease i.e. no previous intervention of common femoral artery with associated superficial femoral artery lesion (Rutherford stages 2-5).
Exclusion Criteria:
- - Non-atherosclerotic conditions (for example: vasculitis, collagen vascular disease, Buerger's disease, radiation).
- Acute limb ischemia.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: angioplasty with stenting
|
dilatation of stenotic arteries and insertion of stent
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
sustained clinical improvement.
Tijdsspanne: 1 year
|
a sustained upward shift of ≥1 category of the Rutherford classification without the need for repeated target lesion revascularization in surviving patients. |
1 year
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Onderzoekstechnieken
- Therapeutica
- Chirurgische procedures, operatief
- Katheterisatie
- Endovasculaire procedures
- Vasculaire chirurgische procedures
- Cardiovasculaire chirurgische procedures
- Minimaal invasieve chirurgische procedures
- Apparatuur en benodigdheden
- Prothesen en implantaten
- Atherectomie
- Angioplastiek
- Stents
Andere studie-ID-nummers
- Soh-Med-22-07-23
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .